Roche: Phase 2/3 Trial of Covid-19 Treatment Ronapreve Met Primary Endpoint
September 30 2021 - 1:52AM
Dow Jones News
By Olivia Bugault
Roche Holding AG said Thursday that its Phase 2/3 trial of
Covid-19 treatment Ronapreve met its primary endpoint.
Results from the trial show that Ronapreve, which is a
combination of two antibodies, casirivimab and imdevimab,
"significantly" reduces the viral load within seven days in
patients who have been hospitalized with Covid-19, the
pharmaceutical company said.
"The efficacy and safety of Ronapreve have been studied across
multiple Phase III clinical trials in non-hospitalized and
hospitalized Covid-19 patients, and in the preventive setting,"
Roche said. "Ronapreve is currently not authorized in patients who
are hospitalized due to Covid-19 infection," it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
September 30, 2021 01:37 ET (05:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
